Anonymous User
Login / Registration

a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2020; 74(6): 553–557. doi: 10.48095/ccgh2020553.

Biosimilar adalimumab FKB-327 in the treatment of inflammatory bowel disease

Milan Lukáš1, Martin Vašátko1, Martin Lukáš1, Martin Kolář1, Dana Ďuricová1, Naděžda Machková1, Karin Malíčková1, Veronika Hrubá1

+ Affiliation


In 2018 year, the patent of original adalimumab expired and a new biosimilar version of adalimumab have been introduced on the Czech market. FKB-327 is one of the new biosimilar adalimumab versions and was approved for all indication of the original drug. This is the first experience with biosimilar adalimumab FKB-327 in IBD patients. Patients cohort comprised from 51 patients included 40 (82%) ones with Crohn´s disease and 9 (18%) ones with ulcerative colitis. Most of the patients (78%) have been naive for biologic therapy. A positive therapeutic effect during the median follow up time (37 weeks) was described in 47 (92%) patients. This drug was tolerated very well and none of the treated patients had to stop prematurely the drug administration due to significant side effects.


idiopatické střevní záněty, biologic therapy, biosimilární adalimumab FKB-327

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users


1. Kolář M, Ďuricová D, Bortlík M et al. Infliximab bio similar (RemsimaTM) in therapy of inflammatory bowel diseases patients: experience from one tertiary IBD centre. Dig Dis 2017; 35 (1–2): 91–100. doi: 10.1159/000453343.
2. Lukáš M, Kolář M, Bortlík M. Biosimilární léčiva v léčbě idiopatických střevních zánětů. In: Tesař V (ed). Biosimilars. Praha: Mladá fronta 2017: 105–122.
3. Lukáš M. První generace bio logických léčiv-anti-TNFa monoklonální protilátky. In: Lukáš M (ed). Pokroky v diagnostice a léčbě idiopatických střevních zánětů. Galén 2019: 137–164.
4. Lukáš M. Biosimilární adalimumab FKB327 (Hulio®). Gastroent Hepatol 2019; 73 (2): 177–178. doi: 10.14735/amgh2019177.
5. Puri A, Niewiarovski A, Arai Y et al. Pharmacokinetics, safety, tolerability and immunogenecity of FKB-327 a new biosimilar medicine of adalimumab / /Humira, in healthy subjects. Br J Clin Pharmacol 2017; 83 (7): 1405–1415. doi: 10.1111/bcp.13245.
6. Genovese MC, Glover J, Matsunga N et al. Efficacy, safety anf immunogenecity in randomized, double blind and open-label extension studies comparing FKB327 an adalimumab bio similar, with adalimumab reference product (Humira-RP) in patients with active rheumatoid arthritis. Arthritis Rheumatol 2017; Suppl 10: 2799.
7. Lukas M, Malickova K, Kolar M et al. Switching from originator adalimumab to the biosimilar SB5 in patients with inflammatory bowel disease: short-term experience from a single tertiary clinical centre. J Crohns Colitis 2020; 14 (7): 915–919. doi: 10.1093/ecco-jcc/jjaa001.

Credited self-teaching test